Donoghue Forlines’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.32M Buy
+4,384
New +$3.31M 0.84% 46
2023
Q2
– Sell
-456
Closed -$375K – 271
2023
Q1
$375K Sell
456
-45
-9% -$33.9K 0.13% 173
2022
Q4
$361K Sell
501
-208
-29% -$153K 0.13% 183
2022
Q3
$488K Sell
709
-1,616
-70% -$1.02M 0.18% 103
2022
Q2
$1.37M Buy
2,325
+1,091
+88% +$709K 0.36% 54
2022
Q1
$862K Buy
+1,234
New +$781K 0.19% 175
2020
Q3
– Sell
-2,308
Closed -$1.44M – 137
2020
Q2
$1.44M Buy
+2,308
New +$1.31M 0.38% 43
2019
Q2
– Sell
-6,604
Closed -$2.71M – 205
2019
Q1
$2.71M Buy
+6,604
New +$2.72M 0.27% 57
2018
Q4
– Sell
-6,631
Closed -$2.68M – 124
2018
Q3
$2.68M Buy
+6,631
New +$2.52M 0.21% 82

Other funds holding REGN

Donoghue Forlines's REGN Position: Q3 2026 in Review

Donoghue Forlines opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2026: 4,384 shares worth $3.32M. The stake represents 0.84% of the portfolio and ranks #46 among its holdings. This is a return to the name: Donoghue Forlines previously reported a position in REGN as recently as Q1 2023.

Donoghue Forlines first reported a position in REGN in Q3 2018 and has held it in 9 quarters since. 1,426 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Donoghue Forlines held 4,384 shares of Regeneron Pharmaceuticals worth $3.32M as of Q3 2026.
  • Regeneron Pharmaceuticals was a new Donoghue Forlines position in Q3 2026.
  • Regeneron Pharmaceuticals made up 0.84% of Donoghue Forlines's portfolio in Q3 2026, its #46 holding.
  • Donoghue Forlines first reported a position in Regeneron Pharmaceuticals in Q3 2018 and has held it in 9 quarters since.
  • 1,426 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Donoghue Forlines's 13F filing for Q3 2026, filed 2 Nov 2026.